vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and COMMERCE BANCSHARES INC (CBSH). Click either name above to swap in a different company.
COMMERCE BANCSHARES INC is the larger business by last-quarter revenue ($475.7M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). COMMERCE BANCSHARES INC runs the higher net margin — 29.8% vs 11.1%, a 18.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.1%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 7.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Commerce Bancshares, Inc. is a regional bank holding company headquartered in Missouri, with principal offices in Kansas City and St. Louis. It is the corporate parent of Commerce Bank, which offers a diversified line of financial services, including business and personal banking, wealth management and investments through its affiliated companies.
ANIP vs CBSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $475.7M |
| Net Profit | $27.5M | $141.6M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 29.8% |
| Revenue YoY | 29.6% | 11.1% |
| Net Profit YoY | 367.5% | 10.5% |
| EPS (diluted) | $1.14 | $0.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $475.7M | ||
| Q4 25 | $247.1M | $449.4M | ||
| Q3 25 | $227.8M | $441.0M | ||
| Q2 25 | $211.4M | $445.8M | ||
| Q1 25 | $197.1M | $428.1M | ||
| Q4 24 | $190.6M | $422.1M | ||
| Q3 24 | $148.3M | $421.4M | ||
| Q2 24 | $138.0M | $414.5M |
| Q1 26 | — | $141.6M | ||
| Q4 25 | $27.5M | $140.7M | ||
| Q3 25 | $26.6M | $141.5M | ||
| Q2 25 | $8.5M | $152.5M | ||
| Q1 25 | $15.7M | $131.6M | ||
| Q4 24 | $-10.3M | $136.1M | ||
| Q3 24 | $-24.2M | $138.0M | ||
| Q2 24 | $-2.3M | $139.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 40.8% | ||
| Q3 25 | 15.9% | 41.9% | ||
| Q2 25 | 6.6% | 44.0% | ||
| Q1 25 | 13.3% | 39.2% | ||
| Q4 24 | -2.3% | 41.2% | ||
| Q3 24 | -13.8% | 42.4% | ||
| Q2 24 | 3.7% | 43.4% |
| Q1 26 | — | 29.8% | ||
| Q4 25 | 11.1% | 31.3% | ||
| Q3 25 | 11.7% | 32.1% | ||
| Q2 25 | 4.0% | 34.2% | ||
| Q1 25 | 8.0% | 30.7% | ||
| Q4 24 | -5.4% | 32.2% | ||
| Q3 24 | -16.3% | 32.8% | ||
| Q2 24 | -1.7% | 33.7% |
| Q1 26 | — | $0.96 | ||
| Q4 25 | $1.14 | $0.86 | ||
| Q3 25 | $1.13 | $1.06 | ||
| Q2 25 | $0.36 | $1.14 | ||
| Q1 25 | $0.69 | $0.98 | ||
| Q4 24 | $-0.45 | $0.83 | ||
| Q3 24 | $-1.27 | $1.01 | ||
| Q2 24 | $-0.14 | $1.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $4.3B |
| Total Assets | $1.4B | $35.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $540.7M | $3.8B | ||
| Q3 25 | $505.8M | $3.8B | ||
| Q2 25 | $436.8M | $3.6B | ||
| Q1 25 | $418.6M | $3.5B | ||
| Q4 24 | $403.7M | $3.3B | ||
| Q3 24 | $405.9M | $3.4B | ||
| Q2 24 | $455.8M | $3.1B |
| Q1 26 | — | $35.7B | ||
| Q4 25 | $1.4B | $32.9B | ||
| Q3 25 | $1.4B | $32.3B | ||
| Q2 25 | $1.3B | $32.3B | ||
| Q1 25 | $1.3B | $32.4B | ||
| Q4 24 | $1.3B | $32.0B | ||
| Q3 24 | $1.3B | $31.5B | ||
| Q2 24 | $920.8M | $30.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $645.1M | ||
| Q3 25 | $44.1M | $129.0M | ||
| Q2 25 | $75.8M | $111.2M | ||
| Q1 25 | $35.0M | $138.6M | ||
| Q4 24 | $15.9M | $577.9M | ||
| Q3 24 | $12.5M | $431.7M | ||
| Q2 24 | $17.4M | $147.4M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $592.4M | ||
| Q3 25 | $38.0M | $113.3M | ||
| Q2 25 | $71.8M | $100.5M | ||
| Q1 25 | $32.5M | $126.0M | ||
| Q4 24 | $13.5M | $531.7M | ||
| Q3 24 | $7.7M | $419.1M | ||
| Q2 24 | $13.0M | $138.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 131.8% | ||
| Q3 25 | 16.7% | 25.7% | ||
| Q2 25 | 34.0% | 22.5% | ||
| Q1 25 | 16.5% | 29.4% | ||
| Q4 24 | 7.1% | 126.0% | ||
| Q3 24 | 5.2% | 99.5% | ||
| Q2 24 | 9.4% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 11.7% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 2.4% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 10.9% | ||
| Q3 24 | 3.2% | 3.0% | ||
| Q2 24 | 3.2% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 4.59× | ||
| Q3 25 | 1.66× | 0.91× | ||
| Q2 25 | 8.87× | 0.73× | ||
| Q1 25 | 2.23× | 1.05× | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 3.13× | ||
| Q2 24 | — | 1.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CBSH
Segment breakdown not available.
